Physician Lauren Lemieux, MD, FACP, DABOM shares the latest science that highlights how GLP-1s can help individuals live healthier lives beyond weight loss. A recent JAMA study shows a reduction in alcohol consumption, and while more research is needed, Dr. Lemieux has observed this trend in her own patients. For employers evaluating obesity treatment solutions, it’s essential to partner with an organization that stays at the forefront of scientific advancements and applies the latest evidence to its clinical care model. Form Health offers a proven, science-backed obesity solution that delivers sustainable weight loss, improved health outcomes, and reduced costs. Contact us at [email protected] to learn more.
GLP-1s for the treatment of substance use disorders like alcohol use disorder highlights how similar neuromodulatory pathways are involved in drug/alcohol addiction and food reward. I’ve seen firsthand alcohol consumption drop significantly in my patients who are taking these medications (prescribed according to FDA criteria for weight loss). I hear comments like “I have no desire to drink” or “I don’t even finish my glass,” and they feel (and are) so much healthier for it! A reduction in alcohol consumption was shown in a recent randomized controlled trial with semaglutide (Hendershot. JAMA. 2025). I believe we will see a broader application of this class of medication to other chronic health conditions in the years to come! JAMA: https://lnkd.in/gmRqx7kk https://lnkd.in/gjjDDvxi